Relevance of Inflammatory Biomarkers in Salivary Gland Cancers Management
Objectives: Preoperative diagnostic investigation of salivary neoplasms leaves a fair share of doubtful cases that complicate the therapeutic choices. The aim of our study was to look for new means to support the decision-making process for their management. Inflammatory biomarkers could play an important role in this process.
Methods: A retrospective chart review of salivary glands tumors was performed between January 2016 and September 2020 in our Department. The samples were divided in 2 groups basing on the histological result after surgery: 191 patients with benign salivary glands tumors (SGbt), and 47 with salivary glands cancer (SGc). 90 patients were randomly selected to form the control group (C group).
Results: Statistically significant increase of platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocite ratio (NLR) and systemic immune-inflammation index (SII) was reported in SGc group compared to SGbt group and control group (p<0.001). Statistical evaluation estabilished optimal threshold for PLR (164,2), NLR (3,11) and SII (517.5) that can discriminate the doubtful cases with specificity of 85-86% and 62% respectively, and sensitivity of 40-45% and 64% respectively.
Conclusion: Inflammatory biomarkers can have a relevant role as diagnostic tools in doubtful cases. They could be performed in the clinical setting for guiding the treatment of these neoplasms.
1.El-Naggar AK, Chan JKC, Grandis JR, Slootweg PJ. Tumours of salivary glands. WHO Classification of Head and Neck Tumours. 4th ed. Lyon, France: IARC Press; 2017. p. 159.
2. Nagler RM, Laufer D. Tumors of the major and minor salivary glands: Review of 25 years of experience. Anticancer Res 1997;17:701–7.
3. Pinkston JA, Cole P. Incidence rates of salivary gland tumors: Results from a population-based study. Otolaryngol Head Neck Surg 1999;120:834–40.
4. Vargas PA, Gerhard R, Araújo Filho VJ, de Castro IV. Salivary gland tumors in a Brazilian population: A retrospective study of 124 cases. Rev Hosp Clin Fac Med Sao Paulo 2002;57:271–6.
5. Horn-Ross PL, Ljung BM, Morrow M. Environmental factors and the risk of salivary gland cancer. Epidemiology 1997;8:414–9.
6. Sun EC, Curtis R, Melbye M, Goedert JJ. Salivary gland cancer in the United States. Cancer Epidemiol Biomarkers Prev 1999;8:1095–100.
7. Peravali RK, Bhat HH, Upadya VH, Agarwal A, Naag S. Salivary gland tumors: A diagnostic dilemma! J Maxillofac Oral Surg 2015;14:438–42.
8. Dhanani R, Iftikhar H, Awan MS, Zahid N, Momin SNA. Role of fine needle aspiration cytology in the diagnosis of parotid gland Tumors: Analysis of 193 cases. Int Arch Otorhinolaryngol 2020;24:508–12.
9. Gudmundsson JK, Ajan A, Abtahi J. The accuracy of fine-needle aspiration cytology for diagnosis of parotid gland masses: A clinicopathological study of 114 patients. J Appl Oral Sci 2016;24:561–7.
10. Kala C, Kala S, Khan L. Milan system for reporting salivary gland cytopathology: An experience with the implication for risk of malignancy. J Cytol 2019;36:160–4.
11. Faquin WC, Rossi ED, Baloch Z, Barkan GA, Foschini M, Kurtycz DFI, et al. The Milan System for Reporting Salivary Gland Cytopathology. Cham, Switzerland: Springer International Publishing AG; 2018.
12. Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res 2014;20:6212–22.
13. Geng Y, Shao Y, Zhu D, Zheng X, Zhou Q, Zhou W, et al. Systemic immune-inflammation index predicts prognosis of patients with esophageal squamous cell carcinoma: A propensity score-matched analysis. Sci Rep 2016;6:39482.
14. Hong X, Cui B, Wang M, Yang Z, Wang L, Xu Q. Systemic Immune-inflammation Index, based on platelet counts and neutrophil-lymphocyte ratio, is useful for predicting prognosis in small cell lung cancer. Tohoku J Exp Med 2015;236:297–304.
15. He W, Yin C, Guo G, Jiang C, Wang F, Qiu H, et al. Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer. Med Oncol 2013;30:439.
16. Sun Y, Zhang L. The clinical use of pretreatment NLR, PLR, and LMR in patients with esophageal squamous cell carcinoma: evidence from a meta-analysis. Cancer Manag Res 2018;10:6167–79.
17. Jonska-Gmyrek J, Gmyrek L, Zolciak-Siwinska A, Kowalska M, Fuksiewicz M, Kotowicz B. Pretreatment neutrophil to lymphocyte and platelet to lymphocyte ratios as predictive factors for the survival of cervical adenocarcinoma patients. Cancer Manag Res 2018;10:6029–38.
18. Rossi ED, Faquin WC. The milan system for reporting salivary gland cytopathology (MSRSGC): An international effort toward improved patient care-when the roots might be inspired by Leonardo da Vinci. Cancer Cytopathol 2018;126:756–66.
19. Lee JJL, Tan HM, Chua DYS, Chung JGK, Nga ME. The Milan system for reporting salivary gland cytology: A retrospective analysis of 1384 cases in a tertiary Southeast Asian institution. Cancer Cytopathol 2020;128:348–58.
20. Rumiati R. Salvadori L. Percezione del rischio e rischio tecnologico-professionale. Risorse Uomo 1999;1.
21. Wu HH, Alruwaii F, Zeng BR, Cramer HM, Lai CR, Hang JF. Application of the Milan system for reporting salivary gland cytopathology: A retrospective 12-year bi-institutional study. Am J Clin Pathol 2019;151:613–21.
22. Baniyash M, Sade-Feldman M, Kanterman J. Chronic inflammation and cancer: Suppressing the suppressors. Cancer Immunol Immunother. 2014;63:11–20.
23. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436–44.
24. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010;6:149–63.
25. Hanahan D, Coussens LM. Accessories to the crime: ;Functions of cells recruited to the tumor microenvironment. Cancer Cell 2012;21:309–22.
26. Wu L, Saxena S, Awaji M, Singh RK. Tumor-associated neutrophils in cancer: going pro. Cancers (Basel) 2019;11:564.
27. Kuzucu İ, Güler İ, Kum RO, Baklacı D, Özcan M. Increased neutrophil lymphocyte ratio and platelet lymphocyte ratio in malignant parotid tumors. Braz J Otorhinolaryngol 2020;86:105– 10.
28. Cheng G, Liu F, Niu X, Fang Q. Role of the pretreatment neutrophil-to-lymphocyte ratio in the survival of primary parotid cancer patients. Cancer Manag Res 2019;11:2281–86.
29. Kawakita D, Tada Y, Imanishi Y, Beppu S, Tsukahara K, Kano S, et al. Impact of hematological inflammatory markers on clinical outcome in patients with salivary duct carcinoma: A multiinstitutional study in Japan. Oncotarget 2017;8:1083–91.
30. Damar M, Dinç AE, Erdem D, Aydil U, Kizil Y, Eravcı FC, et al. Pretreatment neutrophil-lymphocyte ratio in salivary gland tumors is associated with malignancy. Otolaryngol Head Neck Surg 2016;115:988–96.